keyword
MENU ▼
Read by QxMD icon Read
search

"glioblastoma" radiotherapy

keyword
https://www.readbyqxmd.com/read/28332000/neutrophil-lymphocyte-ratio-dynamics-during-concurrent-chemo-radiotherapy-for-glioblastoma-is-an-independent-predictor-for-overall-survival
#1
Matthew Mason, Catherine Maurice, Mairead G McNamara, Minh Thi Tieu, Zarnie Lwin, Barbara-Ann Millar, Cynthia Menard, Normand Laperriere, Michael Milosevic, Eshetu G Atenafu, Warren Mason, Caroline Chung
Elevated neutrophil-lymphocyte ratio (NLR) may predict worse outcomes in cancer, including glioblastoma (GBM). This study assessed whether change in NLR during focal radiotherapy and concomitant temozolomide (RT-TMZ) provides further prognostic information. This was a retrospective review of patients treated with RT-TMZ for histologically confirmed GBM from January 2004 to September 2010. Variables assessed included age, ECOG performance status (PS), dexamethasone use and extent of surgery. Hematological results were collected at baseline, during and 4 weeks post RT-TMZ...
March 22, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28324304/management-of-elderly-patients-with-glioblastoma
#2
REVIEW
Patrick Roth, Dorothee Gramatzki, Michael Weller
PURPOSE OF REVIEW: Glioblastoma represents one of the major challenges in neurooncology and approximately half of the patients are 60 years or older. We summarize the particular situation of elderly glioblastoma patients with a focus on therapeutic considerations. RECENT FINDINGS: Favorable molecular markers such as mutations in the isocitrate dehydrogenase (IDH) 1 or 2 genes are virtually absent in glioblastomas in elderly patients. Treatment options are similar to the situation in young patients and comprise surgical resection, radiation therapy, and alkylating chemotherapy...
April 2017: Current Neurology and Neuroscience Reports
https://www.readbyqxmd.com/read/28320338/the-allosteric-akt-inhibitor-mk2206-shows-a-synergistic-interaction-with-chemotherapy-and-radiotherapy-in-glioblastoma-spheroid-cultures
#3
Ravi S Narayan, Carlos A Fedrigo, Eelke Brands, Rogier Dik, Lukas J A Stalpers, Brigitta G Baumert, Ben J Slotman, Bart A Westerman, Godefridus J Peters, Peter Sminia
BACKGROUND: Glioblastoma multiforme (GBM) is the most common, invasive and deadly primary type of malignant brain tumor. The Phosphatidylinositol-3-Kinase/AKT (PI3K/AKT) pathway is highly active in GBM and has been associated with increased survival and resistance to therapy. The aim of this study is to investigate the effects of AKT inhibition in combination with the current standard of care which consists of irradiation and temozolomide (TMZ) on human malignant glioma cells growing adherent and as multicellular spheroids in vitro...
March 21, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28316990/diagnostic-and-therapeutic-biomarkers-in-glioblastoma-current-status-and-future-perspectives
#4
REVIEW
Wojciech Szopa, Thomas A Burley, Gabriela Kramer-Marek, Wojciech Kaspera
Glioblastoma (GBM) is a primary neuroepithelial tumor of the central nervous system, characterized by an extremely aggressive clinical phenotype. Patients with GBM have a poor prognosis and only 3-5% of them survive for more than 5 years. The current GBM treatment standards include maximal resection followed by radiotherapy with concomitant and adjuvant therapies. Despite these aggressive therapeutic regimens, the majority of patients suffer recurrence due to molecular heterogeneity of GBM. Consequently, a number of potential diagnostic, prognostic, and predictive biomarkers have been investigated...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28315948/-18f-fmiso-pet-study-of-hypoxia-in-gliomas-before-surgery-correlation-with-molecular-markers-of-hypoxia-and-angiogenesis
#5
Lien Bekaert, Samuel Valable, Emmanuèle Lechapt-Zalcman, Keven Ponte, Solène Collet, Jean-Marc Constans, Guénaëlle Levallet, Karim Bordji, Edwige Petit, Pierre Branger, Evelyne Emery, Alain Manrique, Louisa Barré, Myriam Bernaudin, Jean-Sébastien Guillamo
PURPOSE: Hypoxia in gliomas is associated with tumor resistance to radio- and chemotherapy. However, positron emission tomography (PET) imaging of hypoxia remains challenging, and the validation of biological markers is, therefore, of great importance. We investigated the relationship between uptake of the PET hypoxia tracer [18F]-FMISO and other markers of hypoxia and angiogenesis and with patient survival. PATIENTS AND METHODS: In this prospective single center clinical study, 33 glioma patients (grade IV: n = 24, III: n = 3, and II: n = 6) underwent [18F]-FMISO PET and MRI including relative cerebral blood volume (rCBV) maps before surgery...
March 18, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28314386/veliparib-in-combination-with-radiotherapy-for-the-treatment-of-mgmt-unmethylated-glioblastoma
#6
Toni Rose Jue, Kyoko Nozue, Ashleigh J Lester, Swapna Joshi, Lisette B W Schroder, Shane P Whittaker, Sheri Nixdorf, Robert W Rapkins, Mustafa Khasraw, Kerrie L McDonald
BACKGROUND: The O (6) -methylguanine methyltransferase (MGMT) gene is frequently unmethylated in patients with glioblastoma (GBM), rendering them non-responsive to the standard treatment regime of surgery followed by concurrent radiotherapy (RT) and temozolomide. Here, we investigate the efficacy of adding a PARP inhibitor, veliparib, to radiotherapy to treat MGMT unmethylated GBM. METHODS: The inhibition of PARP with veliparib (ABT-888), a potent and orally bioavailable inhibitor in combination with RT was tested on a panel of patient derived cell lines (PDCLs) and patient-derived xenografts (PDX) models generated from GBM patients with MGMT unmethylated tumors...
March 17, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28314273/failure-of-inositol-trispyrophosphate-to-enhance-highly-effective-radiotherapy-of-gl261-glioblastoma-in-mice
#7
Sujatha Iyengar, David Schwartz
BACKGROUND/AIM: Inositol trispyrophosphate (ITPP), reported to cure hepatomas in a preclinical rat model and to have beneficial effects in several other solid tumor models, is currently in clinical trial for liver cancer. We investigated whether aggressive glioblastomas could be effectively treated with ITPP alone or in combination with radiation therapy (RT). MATERIALS AND METHODS: C57Bl/6 mice were intracranially injected with syngeneic GL261 glioblastoma cells and treated with hypofractionated radiation (5 Gy × 3), ITPP, or both...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28314270/global-microrna-expression-profiling-identifies-unique-microrna-pattern-of-radioresistant-glioblastoma-cells
#8
Jakub Ondracek, Pavel Fadrus, Jiri Sana, Andrej Besse, Tomas Loja, Marek Vecera, Lenka Radova, Martin Smrcka, Pavel Slampa, Ondrej Slaby
Glioblastoma multiforme (GBM) is the most aggressive intracranial tumor characterized with infaust prognosis. Despite advances in neurosurgical and radiotherapeutic techniques and chemotherapy, the median overall survival ranges between 12-15 months from diagnosis. The main cause of treatment failure is considered the presence of tumor cells resistant to conventional therapy, mainly radiotherapy. MicroRNAs (miRNAs) are small, non-coding RNAs that function as post-transcriptional regulators of gene expression and have been repeatedly proven to play important roles in pathogenesis and biological features of many cancers, including GBM and its radioresistant phenotype...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28302331/novel-recursive-partitioning-analysis-classification-for-newly-diagnosed-glioblastoma-a-multi-institutional-study-highlighting-the-mgmt-promoter-methylation-and-idh1-gene-mutation-status
#9
Chan Woo Wee, Eunji Kim, Nalee Kim, In Ah Kim, Tae Min Kim, Yu Jung Kim, Chul-Kee Park, Jin Wook Kim, Chae-Yong Kim, Seung Hong Choi, Jae Hyoung Kim, Sung-Hye Park, Gheeyoung Choe, Soon-Tae Lee, Jong Hee Chang, Se Hoon Kim, Chang-Ok Suh, Il Han Kim
BACKGROUND AND PURPOSE: To refine the recursive partitioning analysis (RPA) classification for glioblastoma incorporating the MGMT methylation and IDH1 mutation status. METHODS AND MATERIALS: Three-hundred forty patients were treated with radiotherapy plus concurrent and adjuvant temozolomide in three tertiary-referral hospitals. MGMT methylation and IDH1 mutation status were available in all patients. Methylation of the MGMT (MGMTmeth) and mutation of IDH1 (IDH1mut) were observed in 42...
March 13, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28300718/does-pre-treatment-tumor-growth-hold-prognostic-information-for-glioblastoma-patients
#10
Anne Line Stensjøen, Erik Magnus Berntsen, Vilde E Mikkelsen, Sverre H Torp, Asgeir S Jakola, Øyvind Salvesen, Ole Solheim
BACKGROUND: Glioblastomas are highly aggressive and heterogeneous tumors, both in terms of patient outcome and molecular profile. Magnetic resonance imaging of tumor growth could potentially reveal new insights about tumor biology non-invasively. The aim of this exploratory retrospective study was to investigate the prognostic potential of pre-treatment growth rate of glioblastomas, after controlling for known prognostic factors. METHODS: A growth model derived from clinical pre-treatment post-contrast T1-weighted MRI images was used to divide 106 glioblastoma patients into two groups...
March 11, 2017: World Neurosurgery
https://www.readbyqxmd.com/read/28299344/advances-in-immunotherapy-for-glioblastoma-multiforme
#11
REVIEW
Boyuan Huang, Hongbo Zhang, Lijuan Gu, Bainxin Ye, Zhihong Jian, Creed Stary, Xiaoxing Xiong
Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults. Patients with GBM have poor outcomes, even with the current gold-standard first-line treatment: maximal safe resection combined with radiotherapy and temozolomide chemotherapy. Accumulating evidence suggests that advances in antigen-specific cancer vaccines and immune checkpoint blockade in other advanced tumors may provide an appealing promise for immunotherapy in glioma. The future of therapy for GBM will likely incorporate a combinatorial, personalized approach, including current conventional treatments, active immunotherapeutics, plus agents targeting immunosuppressive checkpoints...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/28298550/limited-role-for-extended-maintenance-temozolomide-for-newly-diagnosed-glioblastoma
#12
Dorothee Gramatzki, Philipp Kickingereder, Bettina Hentschel, Jörg Felsberg, Ulrich Herrlinger, Gabriele Schackert, Jörg-Christian Tonn, Manfred Westphal, Michael Sabel, Uwe Schlegel, Wolfgang Wick, Torsten Pietsch, Guido Reifenberger, Markus Loeffler, Martin Bendszus, Michael Weller
OBJECTIVE: To explore an association with survival of modifying the current standard of care for patients with newly diagnosed glioblastoma of surgery followed by radiotherapy plus concurrent and 6 cycles of maintenance temozolomide chemotherapy (TMZ/RT → TMZ) by extending TMZ beyond 6 cycles. METHODS: The German Glioma Network cohort was screened for patients with newly diagnosed glioblastoma who received TMZ/RT → TMZ and completed ≥6 cycles of maintenance chemotherapy without progression...
March 15, 2017: Neurology
https://www.readbyqxmd.com/read/28298023/alternating-electric-tumor-treating-fields-for-treatment-of-glioblastoma-rationale-preclinical-and-clinical-studies
#13
Sandeep Mittal, Neil V Klinger, Sharon K Michelhaugh, Geoffrey R Barger, Susan C Pannullo, Csaba Juhász
OBJECTIVE Treatment for glioblastoma (GBM) remains largely unsuccessful, even with aggressive combined treatment via surgery, radiotherapy, and chemotherapy. Tumor treating fields (TTFs) are low-intensity, intermediate-frequency, alternating electric fields that have antiproliferative properties in vitro and in vivo. The authors provide an up-to-date review of the mechanism of action as well as preclinical and clinical data on TTFs. METHODS A systematic review of the literature was performed using the terms "tumor treating fields," "alternating electric fields," "glioblastoma," "Optune," "NovoTTF-100A," and "Novocure...
February 24, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/28296618/short-course-radiation-plus-temozolomide-in-elderly-patients-with-glioblastoma
#14
James R Perry, Normand Laperriere, Christopher J O'Callaghan, Alba A Brandes, Johan Menten, Claire Phillips, Michael Fay, Ryo Nishikawa, J Gregory Cairncross, Wilson Roa, David Osoba, John P Rossiter, Arjun Sahgal, Hal Hirte, Florence Laigle-Donadey, Enrico Franceschi, Olivier Chinot, Vassilis Golfinopoulos, Laura Fariselli, Antje Wick, Loic Feuvret, Michael Back, Michael Tills, Chad Winch, Brigitta G Baumert, Wolfgang Wick, Keyue Ding, Warren P Mason
Background Glioblastoma is associated with a poor prognosis in the elderly. Survival has been shown to increase among patients 70 years of age or younger when temozolomide chemotherapy is added to standard radiotherapy (60 Gy over a period of 6 weeks). In elderly patients, more convenient shorter courses of radiotherapy are commonly used, but the benefit of adding temozolomide to a shorter course of radiotherapy is unknown. Methods We conducted a trial involving patients 65 years of age or older with newly diagnosed glioblastoma...
March 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28291159/67cu-radiolabeling-of-a-multimeric-rgd-peptide-for-%C3%AE-v%C3%AE-3-integrin-targeted-radionuclide-therapy-stability-therapeutic-efficacy-and-safety-studies-in-mice
#15
Zhao-Hui Jin, Takako Furukawa, Tomoyuki Ohya, Mélissa Degardin, Aya Sugyo, Atsushi B Tsuji, Yasuhisa Fujibayashi, Ming-Rong Zhang, Tatsuya Higashi, Didier Boturyn, Pascal Dumy, Tsuneo Saga
OBJECTIVE: Copper-67 (Cu) is one of the most promising radionuclides for internal radiation therapy. Globally, several projects have recently been initiated for developing innovative approaches for the large-scale production of Cu. Encouraged by these, we performed Cu-radiolabeling of a tetrameric cyclic Arg-Gly-Asp (cRGD) peptide conjugate, cyclam-RAFT-c(-RGDfK-)4, which selectively targets αVβ3 integrin (αVβ3), the transmembrane receptor involved in tumor invasion, angiogenesis, and metastasis...
April 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28287096/blockade-of-vascular-endothelial-growth-factor-receptors-by-tivozanib-has-potential-anti-tumour-effects-on-human-glioblastoma-cells
#16
Majid Momeny, Farima Moghaddaskho, Narges K Gortany, Hassan Yousefi, Zahra Sabourinejad, Ghazaleh Zarrinrad, Shahab Mirshahvaladi, Haniyeh Eyvani, Farinaz Barghi, Leila Ahmadinia, Mahmoud Ghazi-Khansari, Ahmad R Dehpour, Saeid Amanpour, Seyyed M Tavangar, Leila Dardaei, Amir H Emami, Kamran Alimoghaddam, Ardeshir Ghavamzadeh, Seyed H Ghaffari
Glioblastoma (GBM) remains one of the most fatal human malignancies due to its high angiogenic and infiltrative capacities. Even with optimal therapy including surgery, radiotherapy and temozolomide, it is essentially incurable. GBM is among the most neovascularised neoplasms and its malignant progression associates with striking neovascularisation, evidenced by vasoproliferation and endothelial cell hyperplasia. Targeting the pro-angiogenic pathways is therefore a promising anti-glioma strategy. Here we show that tivozanib, a pan-inhibitor of vascular endothelial growth factor (VEGF) receptors, inhibited proliferation of GBM cells through a G2/M cell cycle arrest via inhibition of polo-like kinase 1 (PLK1) signalling pathway and down-modulation of Aurora kinases A and B, cyclin B1 and CDC25C...
March 13, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28284199/unilateral-malignant-optic-glioma-following-glioblastoma-multiforme-in-the-young-a-case-report-and-literature-review
#17
Chia-Ying Lin, Hsiu-Mei Huang
BACKGROUND: Malignant optic gliomas are rare, but they rapidly become lethal visual pathway tumors. We present the clinical course, treatment, and prognosis of a case of unilateral malignant optic glioma in a young man with a history of brain glioblastoma multiforme (GBM). CASE PRESENTATION: A 21-year-old man, who had GBM 7 years ago complained of a transient shadow in his vision and presented with normal visual acuity but optic disc edema and an enlarged blind spot in the right eye (oculus dexter, OD)...
March 11, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28275120/role-of-mgmt-methylation-status-at-time-of-diagnosis-and-recurrence-for-patients-with-glioblastoma-clinical-implications
#18
Alba A Brandes, Enrico Franceschi, Alexandro Paccapelo, Giovanni Tallini, Dario De Biase, Claudio Ghimenton, Daniela Danieli, Elena Zunarelli, Giovanni Lanza, Enrico Maria Silini, Carmelo Sturiale, Lorenzo Volpin, Franco Servadei, Andrea Talacchi, Antonio Fioravanti, Maria Pia Foschini, Stefania Bartolini, Annalisa Pession, Mario Ermani
BACKGROUND: MGMT methylation status represents a powerful prognostic factor in newly diagnosed glioblastoma (GBM). Recently, its role in recurrent tumors has also been suggested; however, few data investigating the stability of this biomarker during the clinical course of the disease are available. In this study, we evaluated the rate of change of MGMT methylation status between diagnosis and first recurrence in patients who received tumor resection for recurrent GBM. METHODS: We included patients who received temozolomide concurrent with and adjuvant to radiotherapy after diagnosis of GBM and had a second surgery performed at least 3 months after radiotherapy completion...
March 8, 2017: Oncologist
https://www.readbyqxmd.com/read/28273605/a-very-rare-case-report-of-long-term-survival-a-patient-operated-on-in-1994-of-glioblastoma-multiforme-and-currently-in-perfect-health
#19
Riccardo Caruso, Alessandro Pesce, Venceslao Wierzbicki
INTRODUCTION: Glioblastoma multiforme is the most aggressive type of primary brain tumors, but there is a small percentage of patients who have a long-term survival and some exceptional cases who survive decades after surgical removal of tumor. PRESENTATION OF CASE: In 1994, a 44 year-old man, suffering from intense headache and loss of strength of the left arm, was operated for a glioblastoma multiforme in the posterior part of the right frontal lobe. After the operation the patient underwent whole-brain radiotherapy and chemotherapy...
February 20, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28272232/continuous-dose-intense-temozolomide-and-cisplatin-in-recurrent-glioblastoma-patients
#20
Yu Wang, Xiangyi Kong, Yi Guo, Renzhi Wang, Wenbin Ma
In glioblastoma multiforme (GBM), both temozolomide (TMZ) and cisplatin are very active at various toxic levels. Previous studies demonstrated that cisplatin with the standard regimen of TMZ is active in patients suffering from recurrent GBM, generating a moderate level of toxicity. Also, continuous dose-intense TMZ is a helpful therapy for patients with recurrent GBM. We have conducted a research to evaluate the security and effectiveness of cisplatin with constant dose-intense TMZ for reduplicative GBM. The time to progression (TTP) and progression-free survival (PFS) at 6 months (PFS-6) was the major end point...
March 2017: Medicine (Baltimore)
keyword
keyword
75725
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"